venetoclax,pirtobrutinib
eli lilly,valent tech,abbvie,roche
['pirto', 'venetoclax', 'valent ,(-prevalent),(-equivalent),(-bivalent)', 'valent ,(-prevalent)']
next, a tour of novel therapies in richter transformation: - venetoclax with aim to chemosensitise; - pirtobrutinib, non-covalent btki with one of the largest rt cohorts (?durability of single-agent efficacy)
- car-t
- bispecifics
- combinations, including pd1i #asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem